PharmacyCodes



Chlorphenesinum [INN-Latin] en es it fr

Chlorphenesinum [INN-Latin] Brand names, Chlorphenesinum [INN-Latin] Analogs

Chlorphenesinum [INN-Latin] Brand Names Mixture

  • No information avaliable

Chlorphenesinum [INN-Latin] Chemical_Formula

C52H98N16O13

Chlorphenesinum [INN-Latin] RX_link

No information avaliable

Chlorphenesinum [INN-Latin] fda sheet

Chlorphenesinum [INN-Latin] msds (material safety sheet)

Chlorphenesinum_[INN-Latin] MSDS

Chlorphenesinum [INN-Latin] Synthesis Reference

No information avaliable

Chlorphenesinum [INN-Latin] Molecular Weight

2797.3193 g/mol

Chlorphenesinum [INN-Latin] Melting Point

200 - 220 oC

Chlorphenesinum [INN-Latin] H2O Solubility

5.64E+005 mg/L

Chlorphenesinum [INN-Latin] State

Solid

Chlorphenesinum [INN-Latin] LogP

-4.648

Chlorphenesinum [INN-Latin] Dosage Forms

Capsule; Cream; Liquid; Ointment; Powder for solution; Solution; Suspension; Tablet; Tablet (enteric-coated); Tablet (extended-release)

Chlorphenesinum [INN-Latin] Indication

For the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli, particularly Pseudomonas aeruginosa.

Chlorphenesinum [INN-Latin] Pharmacology

Colistin is a polymyxin antibiotic agent. Polymyxins are cationic polypeptides that disrupt the bacterial cell membrane through a detergentlike mechanism. With the development of less toxic agents, such as extended-spectrum penicillins and cephalosporins, parenteral polymyxin use was largely abandoned, except for the treatment of multidrug-resistant pulmonary infections in patients with cystic fibrosis. More recently, however, the emergence of multidrug-resistant gram-negative bacteria, such as Pseudomonas aeruginosa and Acinetobacter baumannii, and the lack of new antimicrobial agents have led to the revived use of the polymyxins.

Chlorphenesinum [INN-Latin] Absorption

Very poor absorption from gastrointestinal tract.

Chlorphenesinum [INN-Latin] side effects and Toxicity

Oral LD50 in rats is 5450 mg/kg. Overdosage with colistimethate can cause neuromuscular blockade characterized by paresthesia, lethargy, confusion, dizziness, ataxia, nystagmus, disorders of speech and apnea. Respiratory muscle paralysis may lead to apnea, respiratory arrest and death.

Chlorphenesinum [INN-Latin] Patient Information

No information avaliable

Chlorphenesinum [INN-Latin] Organisms Affected

Gram-negative bacilli